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Abstract 
4-Amino-2(5H)-furanones were synthesized in high yields over 2 synthetic steps from 
readily available mucochloric acid. These 5-alkyloxy-4-amino-2(5H)-furanones were 
screened in a [125]I-CCK-8 radioligand receptor binding assay for CCK2 affinity and 
novel active ligands in the nanomolar range were identified. SAR was optimized 
leading to the cyclohexyl derivative 25 with an IC50 of 27 nM. Furanone 18 was 
obtained as a stable crystalline material with an IC50 of 85 nM, but occurred a higher 
CCK2 selectivity. It was subsequently tested in the isolated guinea pig ileum (GPI) 
assay with sulfated CCK8 and the CCK antagonizing properties of the ligand were 
confirmed. The CCK2 selective antagonist 18 was found to potentiate analgesia in the 
tail flick assay in mice, for the strong opiate morphine, the partial opiate agonist 
tramadol and the tricyclic antidepressant (TCA) desimipramine. 
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1 Introduction 
Cholecystokinin acts as a neuromodulator as well as gut hormone and CCK-ligands, 
agonists as well as antagonists [1], have been extensively investigated as potential drug 
molecules [2]. CCK-antagonists were studied as growth inhibitors in certain forms of 
cancer [3], as anxiolytics [4], in the treatment of schizophrenia [5], satiety [6] and as 
anti-panic agents [7]. The most simplified agonist, the shortened CCK tetrapeptide, was 
found to induce panic in patients and these effects were blocked by CCK antagonists 
[8]. In addition to anxiety [9] and depression [10], the clinically most relevant 
therapeutic area for CCK antagonists is pain management.  
 
Asperlicin (Figure 1) was the first non-peptidal CCK antagonist lead structure from 
nature and analogues thereof, were studies as CCK ligands [11]. Simplification of the 
lead structure by Merck led to Devazepide [12], a potent CCK1 selective 
cholecystokinin antagonist, containing a 1,4-benzodiazepine template and an indole 
moiety. A phase II trial of Devazepide, which was only published in form of a 
conference report [13] showed a significant enhancement of the effect of opiates in the 
treatment of chronic and severe pain and the CCK neuropeptide pathway was reviewed 
and a featured clinical application for pain [14].  
The indolyl amide of devazepide was replaced by a urea linkage and this resulted in 
Merck’s L-365,260, a CCK2 selective antagonist. Further SAR optimization led to 
Zeria’s Z-360, in which the N- alkyl side chain and the 5- position (cyclohexyl-) was 
optimized for potency (Figure 1). Additionally, a meta-carboxylic acid on the aryl urea 
linkage was introduced to enhance water solubility of this most recent CCK2 antagonist 
[15] (Figure 1).  
 
In our search for new CCK ligands, the 1,4-benzodiazepine template was varied by a 
combinatorial solid phase synthesis [16] and optimised in terms of CCK binding 
affinity [17]. The 1,4-benzodiazepine structure [18] was replaced by an achiral diphenyl 
pyrazolone template, giving novel CCK antagonists with an indole carboxylic acid [19] 
and a phenyl urea moiety [20] and they displayed excellent animal data on anxiety and 
depression [21]. 
 
Figure 1 
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Again, having realized the poor pharmacokinetic properties these agents, a search for a 
completely novel, smaller template with a molecular weight <350, a log p about 3 and 
a polar surface area for membrane penetration of less that 100A, with no urea linkage 
was initiated.  
This resulted in the discovery and SAR- optimization of 4-amino-2(5H)-furanones, 
which are reported here in this publication. For the first time now a totally novel, non-
urea and non- benzodiazepine template [22] was available as potent CCK2 receptor 
antagonist. In vivo evaluation in mice using the tailflick test [23] was initiated with 
tramadol, morphine and finally desimipramine and resulted a relevant potentiation of 
analgesia. 
 
2 Results and discussion 
2.1 Synthesis and SAR - optimisation 
Alkoxy-2(5H)-furanones were generally prepared from mucochloric acid using 
previously developed methods [24]. The overall starting material of this short chemical 
sequence is furfural, which is converted into mucochloric acid on an industrial scale, 
mainly for the use of this intermediate in plant protection and pharmaceuticals. 
 
Scheme 1.  
 
Propargylalcohol, allylalcohol, benzylalcohol and cyclohexyl methanol were reacted in 
presence of toluene under reflux using a Dean Stark trap (Method A). For the iso-
propyloxy-3,4-dichloro-2(5H) furanone excess of the alcohol was applied (Method 2) 
and the intermediate was obtained in large crystals once crystalline.  
The 5-alkoxy (5-propargyl-, allyl-, isopropyloxy-, benzyloxy, and cyclohexyl-
methyloxy-) 2(5H)-furanone intermediates were reacted at slightly elevated 
temperatures with an excess of the parent amine into the desired 4-amino-5 –alkoxy-
2(5H)-furanones 1-26.  
The target molecules were obtained in a low yield for the propargyl- series and in good 
yields for the allyloxy, isopropyloxy and benzyloxy- series. Iso-propyloxy derivatives 
were generally inactive, but crystalline solids, while the benzyloxy series provided 
active and crystalline target molecules. Chemical stability is linked with crystalline 
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properties via the melting point, explaining the desire of the medicinal chemist for white 
crystalline materials. 
 
SAR optimisation 
The propargyl series contained the original lead structure 1, which was identified, when 
the combinatorial library of antibacterial 4-amino-furanones was screened in a CCK 
radioligand binding assay. The 4-isobutyl lead structure 1, which was identified by 
chance, was obtained in a low yield and occurred as sticky brown oil and the 
optimization of structure activity relationships are outlined in Table 1. 
 
The change of the butyl group in this series resulted generally in lower binding affinity 
and the benzyl derivative 2 was found of 2 fold lower and the N-methyl benzyl analogue 
of a similar activity.  
The introduction of piperazinyl-, morpholinyl- and other heterocyclic groups was found 
to result inactive molecules 4 and 5. 
The isobutyl analogue 6 containing an allyloxy-group, was 5 times less potent and the 
closely related n-butyl derivative 8 was found 20 times less potent in the receptor 
binding assay. 
Subsequently the 5-alkoxy C3 unit was varied and a series of isopropyloxy furanones 
9-17 were prepared and tested and an unspecific micromolar activity was determined. 
 
Table 1 
 
The benzyl group is a classical bioisostere of the propargyl group and the benzyl 
analogue of the isobutyl furanone 18 was 3 times more potent than lead structure 1. It 
was also obtained in a good chemical yield as a white, crystalline material.  
For n-butyl and for the secondary butyl 5-benzyloxy-furanones 19 and 20, the 
bioactivity was decreased.  
The pyrazol derivative 21, as well as the cyclopropyl furanone  22 and the cyclopentyl 
derivative 23 were found of a high nanomolar binding affinity, while the cyclohexyl 
analogue 24 had a significantly lower activity. 
For the 5-cyclohexyl methyl aminofuranones series, the methyl analogue 26 occurred 
no binding affinity up to 10 micromolar and the isobutyldrivative 25 was identified as 
the most potent derivative of the entire series. The replacement of the aromatic phenyl 
 5 
group by a cyclohexyl group resulted in enhanced binding affinity for the privileged 
isobutyl amino structure 25. A similar enhancement phenyl versus cyclohexyl was 
previously observed in Z-360, a recent CCK2 antagonist [25].  
 
 Figure 2. 
 
Thus, overall 4 potent CCK ligands in the nanomolar range were identified. The 
furanone 18 occurred an IC50 of 85 nM and displayed 30 times selectivity towards the 
CCK2 receptor. Furanone 21and 23 displayed slightly lower binding affinities and are 
outlined in Figure 2. 
The cyclohexyl derivative 25 showed an enhanced IC50 about 27 nM, but was less 
selective, only 10 times for the CCK2R. It was obtained as an oily solid, which makes 
purification under GMP conditions by recrystallization impossible. 
 
The isobutyl-amino-benzyloxy-furanone 18 was recrystallized from methanol and the 
crystal structure was determined. 
 
Figure 3.  
 
The crystal structure of the high yield - high purity -compound, furanone 18, is outlined 
in Fig 3, supporting excellent manufactoring properties due to appropiate physical 
chemical properties. In the crystal structure, the 5-benzyloxy moiety  is orientated 
below the furanone plain and the 4-amino substituent is located above. 
 
In order to rationalise drug ligand interactions of furanonone 18 with the CCK2/gastrin 
receptor, molecular modeling studies were performed. 
In figure 4 the docking of the furanone 18 into the CCK2 receptor is outlined and key 
drug ligand interactions are analysed as followed:  
Van der Waals interactions of the isobutyl group with Ala106 explain the importance 
of the 2 methyl groups of isobutyl, which both interact with the methyl side chain of 
alanin. Therefore, even minor modifications of the alkyl group resulted in less binding 
affinity. 
 
Figure 4.  
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The carbonyl oxygen of the ligand binds to Arg 106, while the O1 occurred hydrogen 
binding with the alpha H of Trp 105. 
The aromatic benzyl group interacts with a lipophilic pocket of the CCK2 receptor and 
in particular interactions with Ile122, explained an enhanced binding affinity for the 
cyclohexyl ring system of ligand furanone 25. 
 
Functional assay- isolated guinea pig ileum preparation 
In a radiolabelled binding assay with native brain and pancreatic membranes, potent 
and selective ligands were identified. The CCK ligands may act as antagonists, and 
this was investigated using isolated tissue preparations.  
 
Figure 5 
 
Sulfated CCK8 resulted in dose dependent contractions of the GPI, which are outlined 
in fig 5. From 1nM onwards a small response was obtained, which reached plateau 
about 100nM concentrations. 500nM final bath concentration of the test molecule 18 
shifted the curve to the right and 1 micromolar concentration of the furanone 18 resulted 
in nearly a complete inhibition of CCK8s induced contractions, so that it is now 
confirmed, that the ligand furanone 18 acted as CCK antagonist.  
 
The small alkyl amino-benzyloxyfuranone molecule 18 occurred a cLogP about 2.6 
compared with a cLogP of Diazepam of 2.7. Therefore, a sufficient brain penetration 
should be anticipated, essential for CNS activity. A high percentage of preclinical 
candidates drop out due to a poor pharmacokinetic profile and in this is in particular 
complex for a neuromodulator.  
CCK antagonists potentiate the analgesic effects of opiates and for this potent CCK2 
antagonist 18 the scope of analgesia was investigated.  
Tramadol is a partial opiate agonist and also NA/SE reuptake inhibitor. Here, for the 
first time the tricyclic antidepressant desipramine was included in the evaluation of one 
selected CCK antagonist, furanone 18. 
 
In vivo analgesic tests 
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In vivo assay - analgesia potentiation assay [26] in mice for furanone 18 
The effects of CCK on the modulation of pain transmission and the opioid effects are 
well established [27, 28], and typically a low dose of morphine or a high dose of a weak 
opiate agonist will results in a good potentiation of analgesia [29] in the tail immersion 
test [30]. 
 
Figure 6.  
 
The furanone 18 was intraperitoneally injected as a first injection to build up a plasma 
concentration of the CCK antagonist and then, tramadol/ morphine/desimipramine was 
subcutaneously injected and subsequently the analgesic effect was evaluated in the tail 
flick assay (Figure 6). 
 
In all treated groups, no effect on nociception [29] for doses of up to 5 mg/kg was 
observed for the furanone 18 in the tail immersion test [30] as a single agent. 
Administered in conjunction with tramadol/morphine and desimipramine at 0.05 mg 
/kg showed no potentiation of analgesia and a clinically relevant significant effect was 
observed at 0.5 mg /kg.  
For tramadol (20 mg/kg) and concomitant administration of furanone 18 (0.5mg) the 
analgesic effect in the tailflick test is equivalent to a 2 mg/kg dose of morphine.  
For morphine the potentiation of analgesia was also confirmed. Morphine analgesia is 
potentiated by a CCK antagonist and the 2 mg/kg morphine dose is, in presence of 
furanone 18, equivalent to 8 mg/kg morphine, which is therapeutically relevant to 
reduce side effects of opiates. 
Most interestingly, for desimipramine at 0.5 mg/kg a maximum possible effect of 6% 
was determined.  Tricyclic antidepressants, TCA’s, such as desimipramine, show 
clinically a useful analgesic effect in man and in mice this effect is very small (0.3% 
MPE). Here, in presence of 0.5 mg/kg CCK antagonist 18 the 20 mg/kg desimipramine 
dose is equivalent to 20-40 mg tramadol. Thus 0.5 mg/kg of furanone 18 potentiated 
the analgesic effect of a classical TCA by factor 20. 
 
The effects of CCK on the modulation of pain transmission and the opioid effects are 
well established [27, 28] and we have shown here, the useful adjunct therapy of these 
agents in pain management. Previously, it was shown, that the CCK2 antagonist CI-988 
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potentiated the analgesia of morphine and clomipramine [31] and therefore, it may be 
concluded, that this represents a general therapeutic application of CCK2 antagonists. 
Trimipramine is in use as second line treatment for persistent neuropathic pain, which 
still represents an unmet medical need. CCK antagonists also block the development of 
morphine tolerance [32, 33] another further possible therapeutic feature in pain 
management. 
 
3 Conclusions 
Chemically, the bis-substituted amino-furanones are not related to previously known 
CCK antagonizing small organic molecules and they do not contain the widely used 
urea linkage. Our amino-furanones represent a totally novel “new chemical entity” for 
a CCK antagonist, a CNS drug like molecule and most preferred an adjunct in pain 
management.  
The tail immersion test is a robust assay to evaluate analgesia of selected CCK ligands 
in combination with approved analgesics. A classical tissue preparation confirmed 
reliably the antagonism of the ligands. Overall a good in vitro in vivo correlation was 
found.  
During scale up, the yield for the solid isobutyl derivative 18 was increased to >70% 
over 2 steps, and this molecule is available in >99.7% purity and was selected for 
preclinical development. The greater CCK2 selectivity of 18, compared with 25 may 
result in less toxicity due to less interference with the physiological role of 
cholecystokinin, mediated by CCK1 receptors. 
 
4 Materials and Methods 
4.1 Synthesis 
The chemicals were obtained from Aldrich (Gillingham, UK) and Lancaster (Lancaster, 
UK). Atmospheric pressure chemical ionisation mass spectroscopy (APCI), negative or 
positive mode, was carried out using a Hewlett-Packard 5989b quadrupole instrument 
(Vienna, Austria). Proton and Carbon NMR spectra were obtained on a Bruker AC 250 
instrument (Follanden, Switzerland), operating at 250 MHz, calibrated with the solvent 
reference peak or TMS. IR spectra were plotted from KBr discs on a Mattson 300 FTIR 
Spectrometer. Melting points were recorded from a Stuart Scientific (Coventry, UK) 
melting points and are uncorrected.  
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Preparation of 3,4-Dichloro-5-alkoxy-furan-2-(5H)-one building blocks 
Preparation of 3,4-Dichloro-5-propargyloxy-furan-2-(5H)-one A 
Method A - Toluene-Dean-Stark 
To a solution of (10 g, 0.06 mol) mucochloric acid in toluene (50 ml), propargyl alcohol 
(2 eq., 6.5 g, 0.12 mol) and concentrated sulphuric acid (0.2 ml) were added. The 
resulting solution was left for 2 days to reflux using Dean and Stark apparatus. The 
brown oily tar like crude product was analysed by TLC and then quenched with 
saturated sodium bicarbonate solution (50 ml). After leaving the crude mixture to settle 
for 10 minutes, the product was extracted with ether (3 x 50 ml). The organic layers 
were combined and dried using magnesium sulphate. The solvent was removed in 
vacuum, resulting in a dark brown coloured oil. 
 Yield = 61%; 1H NMR (CDCl3) 250MHz:  = 6.11 (s, 1H), 4.58 (m, 2H), 2.96 (t, J = 
2.4 Hz, 1H); 13C NMR (CDCl3)  = 163.1, 147.5, 128.2, 98.6, 78.1, 77.7, 57.4 ppm; 
IR (KBr-disc)  max: 3578, 3293, 2938, 2881, 2122, 1799, 1634, 1450, 1355, 1232, 
1143, 1017, 903, 748, 687 cm-1. 
 
Preparation of 5-Allyloxy-3,4-dichloro-5H-furan-2-one B 
Method A: To a solution of (10 g, 0.06 mol) mucochloric acid in toluene (50 ml), allyl 
alcohol (2 eq., 7.1 g, 0.12 mol) and concentrated sulphuric acid (0.2 ml) were added. 
The resulting solution was left for 2 days according to method A. 
The crude furanone, which was obtained as dark brown coloured oil, was distilled under 
vacuum to give an orange liquid.  
Yield = 69%; 1H NMR (CDCl3) 250 MHz:  = 5.99 (s, 1H), 5.78(m, 1H), 5.27 (m, 1H), 
5.48 (m, 1H), 4.32 (m, 2H) ppm. 13C NMR (CDCl3)  = 163.3, 147.9, 131.9, 124.2, 
119.5, 99.7, 71.1 ppm; IR (KBr-disc)  max: 3413, 3092, 2935, 2870, 2365, 2339, 1796, 
1642, 1334, 1236, 1157, 1020, 899, 778, 748 cm-1. 
 
Preparation of 3,4-Dichloro-5-isopropoxy-5H-furan-2-one C 
Method B, (excess alcohol): To a solution of (10 g, 0.06 mol) mucochloric acid in 
excess isopropanol (60 ml), concentrated sulphuric acid (0.2 ml) was added. The 
resulting solution was left for 2 days to reflux. The brown oily crude product was 
analysed by TLC and then quenched with saturated sodium bicarbonate solution (50 
ml). After leaving the crude mixture to settle for 10 minutes, the product was extracted 
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with ether (3 x 50 ml). The organic layers were combined and dried using magnesium 
sulphate. The solvent was removed in vacuum, resulting in a light dark brown coloured 
oil, which was distilled under vacuum giving a colourless liquid. 
Yield = 73%; 1H NMR (CDCl3) 250 MHz:  = 5.90 (s, 1H), 4.25 (m, 1H), 1.29+1.42 
(d, 6H) ppm. 13C NMR (CDCl3) 250MHz:  = 163.7, 148.0, 123.9, 100.3, 75.1, 22.6, 
22.0 ppm; IR (KBr-disc)  max: 3392, 2975, 2927, 1797, 1645, 1460, 1380, 1326, 1234, 
1160, 1118, 951, 892, 746 cm-1. 
 
Preparation of 5-Benzyloxy-3,4-dichloro-5H-furan-2-one D 
Method A: To a solution of (10 g, 0.06 mol) mucochloric acid in toluene (50 ml), benzyl 
alcohol (2 eq., 13.8 g, 0.12 mol) and concentrated sulphuric acid (0.2 ml) were added 
and reacted according to method A. The crude furanone, which was obtained as a light 
brown coloured oil, was distilled under vacuum giving a yellow liquid. 
Yield = 77%; 1H NMR (CDCl3) 250 MHz:  = 7.48 (m, 5H), 5.94 (s, 1H), 4.88 (m, 2H) 
ppm; 13C NMR (CDCl3) 250MHz:  = 163.3, 147.7 , 135.2, 128.9, 128.5, 126.2, 124.5, 
99.7, 71.4 ppm; IR (KBr-disc)  max: 3432, 3034, 2928, 2371, 2344, 1794, 1642, 1452, 
1330, 1231, 1148, 1022, 909, 746, 697 cm-1. 
 
Preparation of 3,4-Dichloro-5-cyclohexylmethoxy-5H-furan-2-one E 
Method A: To a solution of (10 g, 0.06 mol) mucochloric acid in toluene (50 ml), 
cyclohexyl methanol (2 eq. 13.5 g, 0.12 mol) and concentrated sulphuric acid (0.2 ml) 
were added and the reaction mixture was reacted according to method A. The crude 
furanone was distilled under vacuum to give an orange liquid.  
Yield = 57%; 1H NMR (CDCl3) 250 MHz:  = 5.73 (s, 1H), 3.90 (m, 2H), 1.39-1.76 
(m, 11H) ppm; 13C NMR (CDCl3) 250MHz:  = 161.4, 147.6, 125.3, 101.2 , 68.6, 40.3, 
29.5, 26.7, 25.7 ppm; IR (KBr-disc)  max: 3334, 2926, 2851, 2669, 1794, 1732, 1634, 
1444, 1177, 1018, 729, 697 cm-1. 
 
Preparation of 3-Chloro-4-substituted amino-5-alkyloxyloxy-5H-furan-2-ones 
General Method: 
Building block (2 mmol A-E / 0.41, 0.42, 0.42, 0.52, 0.53g), was dissolved in DMF (2 
ml) and placed into 30 ml glass vials. Amines (5 mmol) were added carefully dropwise 
to each vial. The vials were placed in a heating block and heated to 45oC for 48 hours. 
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The compound was extracted with ether (10 ml) and washed twice with water (10 ml). 
The organic layer was dried using anhydrous magnesium sulphate and removed in 
vacuum to give a dark brown oil, which was purified using column chromatography 
(solvent system: 50/50 ether/petrol ether) to give the desired product. 
  
3-Chloro-4-isobutylamino-5-prop-2-ynyloxy-5H-furan-2-one 1 
Yield = 12% brown oil; MW243.7; MS (APCI(+)): 244/246 (M+1) m/z; 1H NMR 
(CDCl3) 250 MHz:  = 5.92 (s, 1H), 5.19 (bs, NH), 4.41 (s, 2H), 3.28 (m, 2H), 2.55 (m, 
1H), 1.84 (m, 1H), 1.08 (m, 6H) ppm; 13C NMR (CDCl3)  = 166.2 (C=O), 155.3, 
104.5, 94.5, 76.7, 78.1, 56.1, 51.1, 29.6, 19.7 ppm; IR (KBr-disc)  max: 3306, 3103, 
2967, 2937, 2881, 2370, 1748, 1646, 1542, 1458, 1434, 1335, 1126, 969, 747, 701 cm-
1. 
 
4-(benzylamino)-3-chloro-5-(prop-2-ynyloxy)furan-2(5H)-one  2 
36% brown oil; MW: 277.7; MS (APCI(+)): 278, 280 (M+1) m/z.  1H NMR (CDCl3) 
300K : 7.36 (m, 5H); 5.98 (s, 1H), 5.20 (s, NH), 4.66 (s, 2H), 4.45 (m, 1H), 4.41 (m, 
2H), 2.55( m, 1H), ppm. 13C NMR (CDCl3)  = 168.1, 155.8, 135.6, 129.0, 128.6, 126.3, 
108.3, 96.6, 78.2, 76.6, 54.9ppm. IR (KBr-disc)  max: 3380, 3283, 2358, 2338, 1752, 
1646, 1455, 1326, 1123, 971 & 695 cm-1. 
 
4-(Benzyl-methyl-amino)-3-chloro-5-prop-2-ynyloxy-5H-furan-2-one 3 
Yield = 49%oily solid; MW: 291.7; MS (APCI(+)): 292/294 (M+1) m/z 
1H NMR (CDCl3) 250 MHz:  = 7.16-7.41 (m, 5H), 5.96 (s, 1H), 4.70 (m, 2H, 4.40 (m, 
2H), 3.04 (s, 3H), 2.48(m, 1H) ppm; 13C NMR (CDCl3)  = 168.2, 155.6, 135.7, 129.0, 
128.6, 127.3, 107.3, 94.6, 78.1, 76.9, 55.9, 38.1 ppm. IR (KBr-disc)  max: 3441, 3296, 
3037, 2930, 2374, 2343, 2128, 1766, 1643, 1460, 1419, 1353, 1270, 1229, 1116, 983, 
747, 703 cm-1. 
 
4-(4-Benzyl-piperazin-1-yl)-3-chloro-5-prop-2-ynyloxy-5H-furan-2-one 4 
Yield = 50%; MP: 120-123 oC; MW: 346.8; MS (APCI(+)): 346/348 (M+1) m/z 
1H NMR (CDCl3) 250 MHz:  = 7.18-7.38 (m, 5H), 5.87 (s, 1H), 4.36 (s, 2H), 3.76 (m, 
4H), 3.51 (s, 2H), 2.42-2.39 (m, 5H) ppm. 13C NMR (CDCl3) 250MHz:  = 168.1, 
154.0, 137.2, 129.2, 128.4, 127.5, 103.0, 94.3, 76.9 76.8, 62.7, 55.7, 52.7, 47.5 ppm. 
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IR (KBr-disc)  max: 3253, 2935, 2815, 2126, 1758, 1446, 1347, 1277, 1111, 985, 
849, 740, 693 cm-1. 
 
3-Chloro-4-(2,6-dimethyl-morpholin-4-yl)-5-prop-2-ynyloxy-5H-furan-2-one 5 
Yield = 47%; Oily Solid; MW: 285.7; MS (APCI(+)): 286/288 (M+1) m/z; 1H NMR 
(CDCl3) 250 MHz:  = 5.94 (s, 1H), 4.36 (s, 2H), 3.89-4.25 (m, 2H), 3.58-3.85 (m, 2H), 
2.51-2.98 (m, 3H), 1.46 (m, 6H) ppm. 13C NMR (CDCl3):  = 170.4, 153.7, 104.2, 94.3, 
77.8, 77.6, 66.0, 55.8, 52.6, 18.5, 18.4 ppm. IR (KBr-disc)  max: 3484, 3255, 2981, 
2928, 2883, 2366, 2108, 1743, 1639, 1267, 1083, 981, 751, 697 cm-1. 
 
 
5-Allyloxy-3-chloro-4-isobutylamino-5H-furan-2-one 6 
Yield = 62%; Oily Solid; MW: 245.7; MS (APCI(+)): 188/190 (M+), 246/248 (M+1) 
m/z; 1H NMR (CDCl3) 250 MHz:  = 5.89 (m, 1H), 5.73 (s, 1H), 5.34 (m, 2H), 4.79 
(bs, NH),  4.27 (m, 2H), 3.22 (bs, 2H), 1.83 (m, 1H), 1.16-0.98(m, 6H) ppm; 13C NMR 
(CDCl3):  = 172.1, 156.7, 132.2, 119.6, 108.0, 95.9, 69.3 , 51.0, 29.6, 19.7 ppm; IR 
(KBr-disc)  max: 3296, 3088, 2978, 2978, 2939, 2881, 1753, 1649, 1546, 1467, 1338, 
1150, 972, 709 cm-1. 
  
5-Allyloxy-4-sec-butylamino-3-chloro-5H-furan-2-one 7 
Yield = 49%; Oily Solid; MW: 245.7; MS (APCI(+)): 190/192 (M+), 246/248 (M+1) 
m/z; 1H NMR (CDCl3) 250 MHz:  = 5.89 (m, 1H), 5.74 (s, 1H), 5.28 (m, 2H), 4.27 
(m, 2H), 1.68 (m, 2H), 1.82 (m, 3H), 0.99 (t, J = 4.6 Hz, 3H) ppm; 13C NMR(CDCl3): 
 = 168.3, 153.5, 132.5, 119.0, 106.3, 96.5, 69.6, 49.6, 30.5, 21.4, 10.3 ppm. IR (KBr-
disc)  max: 3296, 3088, 2978, 2978, 2939, 2881, 1753, 1649, 1546, 1467, 1338, 1150, 
972, 709 cm-1. 
 
5-Allyloxy-4-butylamino-3-chloro-5H-furan-2-one 8 
Yield = 57%; Oily Solid; MW: 245.7(APCI(+)): 188/190 (M+), 246/248 (M+1) m/z 
1H NMR (CDCl3) 250 MHz:  = 5.90 (m, 1H), 5.76 (s, CH), 5.32 (m, 2H), 4.29 (m, 2H), 
3.43(bs, 2H), 1.63 (m, 2H), 1.38 (m, 2H), 0.98 (t, J = 8.2 Hz, 3H) ppm. 13C NMR 
(CDCl3)  = 165.9, 151.3, 132.4, 119.4, 105.6, 96.2, 69.6, 43.6, 32.7, 19.7, 13.7 ppm. 
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IR (KBr-disc)  max: 3332, 3095, 2974, 2941, 2892, 1754, 1655, 1540, 1457, 1333, 
1227, 1138, 1087, 969, 748, 700 cm-1. 
 
5-Benzyloxy-3-chloro-4-isobutylamino-5H-furan-2-one 18 
Yield = 76%; MP: 105-107 oC; MW: 295.8; MS (APCI(+)): 188/190 (M+), 296/298 
(M+1) m/z; 1H NMR (CDCl3) 250 MHz:  = 7.01-7.49 (m, 5H), 5.79 (s, CH), 5.10 (bs, 
NH), 4.71(bs, 2H), 3.22 (m, 2H), 1.79 (m, 1H), 0.97 (m, 6H) ppm; 13C NMR (CDCl3): 
 = 170.4, 170.4, 135.4, 128.8, 106.3, 95.6, 70.4, 51.0, 29.5, 19.7 ppm.  
IR (KBr-disc)  max: 3460, 3252, 2977, 2937, 2877, 2368, 2341, 1741, 1631, 1433, 
1353, 1329, 1255, 1128, 1028, 961, 750, 703 cm-1. 
     
C15H18ClNO3 
Mr = 295.75 
T = 293(2) K 
Tabular 
0.20 x 0.15 x 0.05 mm 
Colourless 
Mo K radiation:  = 0.71073 Å 
Monoclinic  
P21/c 
a = 11.420(5) Å  
b = 10.736(2) Å  
c = 12.798(5) Å 
 = 102.83(4) o 
V = 1529.9(9) Å3 
Z = 4 
Dx = 1.284 Mg/m
-3 
Dm not measured 
R [F2 > 2(F2)] = 0.0791 
wR(F2) = 0.1845 
3207 reflections  
187 parameters 
 
 
Selected geometric parameters (Å, o) 
 
Cl(7)-C(2)  
O(5)-C(1)  
O(5)-C(4)  
O(6)-C(1)  
 
1.707(7) 
1.365(8) 
1.432(7) 
1.202(7) 
O(12)-C(4)  
C(3)-N(8)  
C(2)-C(3)  
1.386(7) 
1.331(7) 
1.354(9) 
C(4)-O(12)-C(13)  
O(12)-C(13)-C(14)  
N(8)-C(3)-C(4)  
O(12)-C(4)-O(5)  
113.7(5) 
108.2(6) 
124.5(6) 
111.5(5) 
O(6)-C(1)-O(5)  
C(1)-C(2)-Cl(7)  
C(3)-C(2)-Cl(7)  
C(3)-N(8)-C(9)          
120.3(5) 
122.9(5) 
127.0(5) 
124.5(6) 
 
 
5-Benzyloxy-4-butylamino-3-chloro-5H-furan-2-one 19 
Yield = 68%; MP: 109-112 oC; MW: 295.8; MS (APCI(+)): 188/190 (M+), 296/298 
(M+1) m/z; 1H NMR (CDCl3) 250 MHz:  = 7.39 (m, 5H), 5.74 (s, 1H), 4.64 (m, 3H), 
 14 
3.31 (bs, 2H), 1.569 (m, 2H), 1.39 (m, 2H), 0.89 (t,  J = 6.6 Hz, 3H) ppm. 13C NMR 
(CDCl3)  = 171.4 , 153.4 , 135.5 , 128.8, 128.1, 124.5, 107.5 , 95.5 , 70.3 , 43.7, 29.5 
, 19.7, 13.7 ppm; IR (KBr-disc)  max: 3419, 2067, 3028, 2928, 2371, 2338, 1794, 
1642, 1502, 1456, 1327, 1234, 1144, 1022, 972, 902, 750, 707 cm-1. 
 
5-Benzyloxy-4-sec-butylamino-3-chloro-5H-furan-2-one 20 
Yield = 64%; MP: 93-96 oC; MW: 295.8; MS (APCI(+)): 188/190 (M+), 296/298 
(M+1) m/z; 1H NMR (CDCl3) 250 MHz:  = 7.30 (m, 5H), 5.73 (s, 1H), 5.11 (bs, NH), 
4.68 (m, 2H), 4.40 (bs, NH), 3.49(bs, 1H), 1.46 (m, 2H), 1.16 (m, 3H), 0.84 (m, 3H) 
ppm; 13C NMR (CDCl3)  = 169.3, 155.5, 135.6,128.9, 128.7, 124.3, 105.9, 95.7, 70.2, 
51.1, 30.5, 21.6, 21.6 ppm; IR (KBr-disc)  max: 3272, 3085, 2977, 2929, 2880, 2368, 
1732, 1632, 1560, 1454, 1348, 1231, 1123, 966, 749, 700 cm-1. 
 
5-Benzyloxy-3-chloro-4-(3-methyl-pyrazol-1-yl)-5H-furan-2-one 21 
 
Yield = 76%; MP: 89-91 oC; MW: 304.7; MS (APCI(+)): 305/307 (M+1) m/z; 1H NMR 
(CDCl3) 250 MHz:  = 8.25 (m, 1H), 7.31(m, 5H), 6.49 (s, 1H) 6.40 (m, 1H), 4.94 (m, 
2H), 2.41 (s, 3H) ppm. 13C NMR (CDCl3):  = 165.7, 153.7, 147.3, 135.5 130.9, 128.7, 
128.6, 128.55, 111.3, 102.7, 99.1, 72.6, 13.7 ppm; IR (KBr-disc)  max: 3440, 3176, 
2950, 2941, 2885, 2362, 2336, 1790, 1674, 1551, 1443, 1324, 1264, 1122, 1016, 983, 
735, 695 cm-1. 
 
 
5-Benzyloxy-3-chloro-4-cyclopropylamino-5H-furan-2-one 22 
 
Yield = 81%; MP: 104-107 oC; MW: 279.7; MS (APCI(+)): 278/280 (M+) m/z 
1H NMR (CDCl3) 250 MHz:  = 7.80 (m, 5H), 5.95 (s, 1H), 4.84 (m, 3H), 2.99 (m, 1H), 
0.79 (m, 7H) ppm; 13C NMR (CDCl3)  = 161.4, 153.4 , 133.6, 128.8, 128.7, 126.4, 
106.1, 95.7, 70.8, 25.5, 18.3 ppm; IR (KBr-disc)  max: 3453, 3265, 3071, 2935, 2864, 
2366, 1788, 1742 1636, 1442, 1348, 1245, 983, 753, 701 cm-1. 
 
 
5-Benzyloxy-3-chloro-4-cyclopentylamino-5H-furan-2-one 23 
 
Yield = 78%; MP: 101-103 oC; MW: 307.8 ;MS (APCI(+)): 284/286 (M+), 306/308 
(M+1) m/z; 1H NMR (CDCl3) 250 MHz:  = 7.49 (m, 5H), 5.78 (s, 1H), 4.78 (m, 2H), 
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4.01(bs, NH), 1.33-2.15 (m, 8H ppm; 13C NMR (CDCl3)  = 165.2 , 151.3, 135.5, 128.8, 
128.2 124.6, 104.2 , 95.6, 70.2, 55.3, 34.6, 23.7 ppm;  IR (KBr-disc)  max: 3459, 3306, 
3070, 2961, 2859, 2367, 2342, 1735, 1626, 1547, 1352, 1231, 1144, 1007, 959, 758, 
707 cm-1. 
 
5-Benzyloxy-3-chloro-4-cyclohexylamino-5H-furan-2-one 24 
 
Yield = 49%; Oily Solid; MW: 321.8; MS (APCI(+)): 322/324 (M+) m/z; 1H NMR 
(CDCl3) 250 MHz:  = 7.30 (m, 5H), 5.78 (s, 1H), 4.96 (bs, NH), 4.76 (m, 2H), 1.04-
2.18 (m, 10H) ppm; 13C NMR (CDCl3)  = 167.5, 155.5, 135.5, 128.7, 128.4, 124.2, 
104.5, 95.6, 67.0, 52.7, 34.5, 25.5, 25.1 ppm; IR (KBr-disc)  max: 3293, 3067, 2941, 
2861, 2375, 2355, 1754, 1648, 1550, 1446, 1337, 1231, 1134, 1091, 955, 746, 700 cm-
1. 
 
 3-Chloro-5-cyclohexylmethoxy-4-isobutylamino-5H-furan-2-one 25 
Yield = 59%; MP: 119-122 oC; MW: 301.8; MS (APCI(+)): 206/208 (M+), 302/304 
(M+1) m/z; 1H NMR (CDCl3) 250 MHz:  = 5.75 (s, 1H), 4.89 (bs, NH), 3.53 (m, 1H), 
3.49 (m, 1H), 3.37 (bs, 2H), 2.76 (bs, 1H), 1.53-1.79 (m, 5H), 0.81-1.42 (m, 12H) ppm; 
13C NMR (CDCl3)  = 165.5, 153.6, 104.2, 97.0, 74.0, 51.1 , 37.7 , 29.8, 29.7, 27.0, 
25.7, 19.74, 19.71ppm; IR (KBr-disc)  max: 3285, 2971, 2933, 2863, 2370, 1745, 
1678, 1630, 1470, 1333, 1256, 1147, 1025, 948, 750, 718 cm-1. 
 
3-Chloro-5-cyclohexylmethoxy-4-methylamino-5H-furan-2-one 26 
Yield = 55%; MP: 117-120 oC; MW: 259.7; MS (APCI(+)): 164/166 (M+1), 260/262 
(M+) m/z; 1H NMR (CDCl3) 250 MHz:  = 5.72 (s, 1H), 4.89 (bs, NH), 3.49 (m, 1H), 
3.37 (m, 1H), 3.23 (m, 3H), 2.76 (bs, 1H), 1.72 (m, 5H), 0.77-1.39 (m, 6H) ppm; 13C 
NMR (CDCl3)  = 164.1, 151.3, 102.6 , 97.0, 74.2, 37.7, 30.6, 29.7, 27.0, 25.7 ppm. IR 
(KBr-disc)  max: 3267, 2925, 2848, 2370, 2338, 1742, 1684, 1632, 1451, 1329, 1255, 
1159, 1016, 949, 755, 716 cm-1. 
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4.2 Pharmacology 
Cholecystokinin binding assay, [125]I-CCK-8 receptor binding assay 
CCK1 and CCK2 receptor binding assays were performed, by using guinea pig cerebral 
cortex (CCK2) or rat pancreas (CCK1).  Male guinea pig brain tissues were prepared 
according to the modified method described by Saita et al [34]. Pancreatic membranes 
were prepared as described by Charpentier et al [35].  
Tissues were homogenized in ice cold sucrose (0.32 M, 25 ml) for 15 strokes at 500 
rpm and centrifuged at 13000 rpm for 10 minutes. The supernatant was re-centrifuged 
at 13000 rpm for 20 minutes. The resulting pellet was re-dispersed to the required 
volume of buffer at 500 rpm and stored in aliquots at 70oC.  
Binding was achieved using radioligand 125I-Bolton-Hunter labelled CCK, NEN at 25 
pM. The samples were incubated with membranes (0.1 mg/ml) in 20 mM Hepes, 1mM 
EGTA, 5 mM MgCl2, 150 mM NaCl, at pH 6.5 for 2 hrs at RT and then centrifuged at 
11000 rpm for 5 minutes. The membrane pellets were washed twice with water and the 
bound radioactivity was measured in a Packard Cobra counter. 
 
Isolated tissue preparation 
Adult male guinea pigs, weighing 200-250 g, were used and from the abdomen of the 
animals, the ileum was carefully excised at a site 15cm away from the ileocaecal 
junction and washed with physiological solution. The mesentery of the ileum was 
removed and the ileal lumen was gently flushed with tyrode’s solution to clear luminal 
contents. The prepared isolated tissue was rapidly incubated in Tyrode’s solution 
maintained at 37oC and gassed with 95%O2/5%CO2. 
Tyrode’s solution of the following quantity was freshly prepared daily (g/l): NaCl, 8.0; 
KCl, 0.2; CaCl2, 0.2; MgSO4, 0.1; NaH2PO4, 0.05; NaHCO3, 1.0; Glucose, 1.0. Stock 
solutions of test compounds were prepared weekly, diluted to required concentration as 
required and stored at a temp of 4oC. 
From the isolated tissue preparation, ileal strips of appropriate length were mounted 
vertically in organ bath containing tyrode’s solution, under a tension of 1g and allowed 
to equilibrate for 30 minutes. One end of the strip was attached to the hook at the bottom 
of the organ bath and the other end connected by a thread to the external isometric force 
transducer. During equilibration, tension was continuously adjusted to 1g when 
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required and the Tyrode’s solution in the organ bath was changed every 20 minutes. All 
spontaneous contractions of longitudinal muscles were recorded with the aid of an 
isometric transducer linked to a power lab chart computer unit.  
Effects on CCK-8 stimulated isolated guinea pig ileum 
To study the effect of furanone 18 on strips prepared from guinea pig ileum, CCK8S 
was dissolved in distilled water to prepare a stock solution of 500µM solution, from 
which cumulative additions of increasing concentrations (0.1 nM, 1 nM, 5 nM, 10 nM, 
20 nM, 30 nM, and 40 nM) were tested to plot a dose response curve. Test compounds  
and Lorglumide/L365,260 as standard were added to the organ bath 10 minutes before 
exposure to the next CCK8S serial concentrations. 
 
Animal studies 
Experiments were conducted in male standard IRC mice obtained from the animal 
house, Faculty of Medicine, Khon Kaen University. Each experimental group consisted 
of 6 animals and the treatment procedures were approved by the ethical committee, 
Faculty of Medicine, Khon Kaen University (BEA030699). 
Mice were intraperitoneal injected with either test compound dissolved in 5% DMSO 
at the volume not more than 0.2 ml/animal. At 30 min after treatment, animals were 
tested as described in the following sections. 
 
Nociception test 
The tail immersion test: The thermal response latency was measured by the tail 
immersion test. The animals were placed into individual restraining cages leaving the 
tail hanging freely. The tail was immersed into water preset at 50oC. The response time, 
at which the animal reacted by withdrawing its tail from water, was recorded and the 
cut-off time was 10 sec in order to avoid damaging the animal’s tissue. The base line 
withdrawal thresholds (BT) were recorded prior to the first injection. Test thresholds 
(TT) were measured 60 min after the second injection. The test thresholds were 
expressed as a percentage of Maximal Possible Effect (% MPE) using the equation:  
% MPE = {(TT-BT) / (45-BT)} x 100 
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DMSO (5 %), furanone (in 5 % DMSO) was intraperitoneally injected as the first 
injection. Twenty min after the first, the second injection was done by subcutaneously 
injected with tramadol at either 10, 20 or 40 mg/kg body weight.  
 
Molecular modeling 
For target preparation the protein structures, pdb identifier 1HZN for the CCK1 and 
1L4T for the CCK2 –gastrin receptor were downloaded from the protein data bank 
(www.rcs.org) and docking was performed using Autodock Vina and Hex. After 
several docking trials for the CCK2 receptor the results were analysed and visualized 
using Chimera and Designer studio 4.5. After visual inspection and scores, results 
were presented to understand drug ligand interaction with the CCK2 receptor. 
 
Statistical methods 
The data were expressed as mean + SD and one-way analysis of variance (ANOVA) 
and supplementary Tukey test for pairwise comparison were tested to determine for any 
significant difference at p< 0.05. 
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Figure 1. Drug design from Asperlicin, an isolated natural product, via Devazepide, a 
CCK1 selective antagonist, to a CCK2 selective urea based antagonist, L-365,260. 
Drug optimisation from L-365,260 towards Z-360, a CCK2 antagonist with improved 
potency and water solubility. 
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Scheme 1. See experimental section for furanone – building blocks. Synthetic route for 
the formation of 5-alkoxy-4-aminofuran-2(5H)-ones 1-26.  
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Entry R1= R2= CCK-B CCK-A 
1 Propargyl- Isobutylamino- 220±29 >10000 
2 Propargyl- Benzylamino- 470±34 - 
3 Propargyl- N-methyl-benzylamino- 280±32 - 
4 Propargyl- Benzylpiperazinyl- >10000 - 
5 Propargyl- 3,5-dimethylmorpholino- >10000 - 
6 Allyl- Isobutylamino- 1239±103 - 
7 Allyl- Sec butylamino- >10000 - 
8 Allyl- n-butylamino- 4312±242 - 
9 Isopropyl- Isopropylamino- 1200  - 
10 Isopropyl- Cyclopropylamino- 4300 - 
11 Isopropyl- Cyclopentylamino- 5700 - 
12 Isopropyl- Cyclohexylamino- 2300 - 
13 Isopropyl- Phenylethylamino- 6700 - 
14 Isopropyl- Benzylamino- 1300 - 
15 Isopropyl- N-methyl-benzylamino- 2700 - 
16 Isopropyl- Dimethylanilino- 2600±120 - 
17 Isopropyl- Indolino- 5400 - 
18 Benzyl- Isobutylamino- 85±11 2566±343 
19 Benzyl- n-butylamino- 548±43 - 
20 Benzyl- Sec butylamino- 627±43 - 
21 Benzyl- 3-methylpyrazolo- 162±13 2344±321 
22 Benzyl- Cyclopropylamino- 263±18 >10000 
23 Benzyl- Cyclopentylamino- 180±33 2598±436 
24 Benzyl- Cyclohexylamino- 503±48 - 
25 Cyclohexylmethyl- Isobutylamino- 27±6 260±21 
26 Cyclohexylmethyl- Methylamino- >10000 - 
 
Table 1. SAR optimisation with respect to receptor binding affinity for 4-amino-5-
alkoxy-furan-2(5H)-ones 1-26. IC50 in nM. N=3. 
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Figure 2. Overview of nanomolar CCK2 ligands. 
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Figure 3. Crystal structure of 5-Benzyloxy-3-chloro-4-isobutylamino-5H-furan-2-one 
18, sample recrystallised from methanol. 
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Figure 4. Docking of the furanone 18 into the active site of the CCK2 receptor. 
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Figure 5. Isolated GPI. Cummulative log concentration response curves to CCK8S only 
(●) and CCK8S in the presence of 18: 0.5 µM (▲), 1.0 µM (▼) on the guinea pig ileum, 
expressed as change of tension in g. Each point represents the mean and the standard 
errors obtained from three different experiments. 
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Figure 6. Maximum possible effect (MPE) of 3 doses of furanone 18 in the tail flick 
test in mice in % MPE for tramadol-, morphine- and desimipramine potentiation. 
 
 
